Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Cancer Discov. 2020 Jan 23;10(3):382–393. doi: 10.1158/2159-8290.CD-19-0608

Figure 1. Evidence for the ISGylation-activating enzyme UBA7 as a tumor suppressor.

Figure 1.

A, Kaplan-Meier curves showing the correlation between Relapse Free Survive (RFS) and UBA7 expression in breast cancer (Affymetrix ID 203281_at UBA7).

B, Kaplan-Meier curves showing the correlation between RFS and UBA7 expression in triple negative breast cancer (TNBC) (Affymetrix ID 203281_at UBA7).

C, Expression of Isg15 and Uba7 in tumors compared with their adjacent normal tissues from PyVmT WT mice at 10 weeks of age (n = 5). p, paired t-test.

D, Representative photograph of PyVmT/WT and PyVmT/Uba7 KO mice at 10 weeks of age.

E, Percentage of mice with largest tumor diameter above 0.5 cm (n = 10/group).

F, Tumor volume of largest tumors in PyVmT/WT and PyVmT/Uba7 KO mice at 10 weeks of age (n = 10/group). p, student’s t-test.

G, Representative level of ISG15 and protein ISGylation in tumor tissue from PyVmT/WT and PyVmT/Uba7 KO mice.

H, Tumor burden (total tumor weight/body weight) distribution of PyVmT/WT (n = 25) and PyVmT/Uba7 KO (n = 23) mice at the endpoint. p, Fisher’s exact test.

I&J, Number of spontaneous lung metastasis in PyVmT/WT and PyVmT/Uba7 KO mice. Serial lung sections were stained with H&E (n = 5–6). p, student’s t-test.